ClinicalTrials.gg

Program

AMT-676

A development code.

Its studies are mostly in Colorectal Neoplasms, led by Multitude Therapeutics.

Furthest: phase 2, since Mar 5, 20262 company-led studies, 2 open or runningNext primary completion: May 15, 2027 (early phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Multitude Therapeutics22 open or runningphase 2since Mar 5, 2026May 1, 2024May 15, 2027early phase 1 · NCT06400485

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 1, 2024First study: early phase 1 study in Advanced Solid TumorsFirst studyNCT06400485 · 24 planned · American Samoa, Australia, China
  2. Mar 5, 2026Phase 2 study in Colorectal NeoplasmsPhase 2 reachedNCT07474727 · 180 planned · China

Ahead

  1. May 15, 2027Primary completion: early phase 1 study in Advanced Solid TumorsNCT06400485
  2. Sep 30, 2027Primary completion: phase 2 study in Colorectal NeoplasmsNCT07474727

TargetBeta

CDH17 →read by rule
“First-in-Human, Phase I/II Study of AMT-676, an Anti CDH17 Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors”study text, by rule · the study

Other programs on CDH17

ProgramCompanyFurthest phaseStudies
Anti-CDH17 Antibody-drug Conjugate HS-20110Hansoh Pharmaceutical Groupphase 22
Anti-CDH17/MF-6 Antibody-drug Conjugate 7MW4911ruleMabwell (Shanghai) Biosciencephase 22
Anti-CDH17/Topoisomerase I Inhibitor Antibody-drug Conjugate DB-1324ruledualitybio-incphase 21
LM-350Sino Biopharmaceuticalphase 21
Anti-CDH17 Antibody-drug Conjugate YL217ruleMediLink Therapeutics (Suzhou)phase 11
Anti-CDH17/Exatecan Antibody-drug Conjugate ARR-217rulearrivent-biopharma-incphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07474727Colorectal Neoplasms · China2RecruitingSep 30, 2027180
NCT06400485Advanced Solid Tumors · American Samoa, Australia, ChinaEarly 1RecruitingMay 15, 202724

How it is read

Names in the registry

  • “AMT-676”, 2 entries

Codes read as this program: AMT676.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.